Clinicopathological Profile of Low-Grade B Cell Non-Hodgkin Lymphoma in Tertiary Health Care in West Java Indonesia
暂无分享,去创建一个
[1] J. Zaucha,et al. First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4 , 2019, British journal of haematology.
[2] D. Bron,et al. Marginal zone lymphomas: second most common lymphomas in older patients. , 2019, Current opinion in oncology.
[3] M. Albayrak,et al. Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma , 2019, Indian Journal of Hematology and Blood Transfusion.
[4] P. Jain,et al. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management , 2019, American journal of hematology.
[5] E. Steliarova-Foucher,et al. Global patterns and trends in the incidence of non-Hodgkin lymphoma , 2019, Cancer Causes & Control.
[6] S. Malek,et al. Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.
[7] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[8] C. Suh,et al. Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience , 2018, Blood research.
[9] A. Freedman. Follicular lymphoma: 2018 update on diagnosis and management , 2018, American journal of hematology.
[10] Pio Zeppa,et al. Non-Hodgkin Lymphoma. , 2020, Monographs in clinical cytology.
[11] L. Quintanilla‐Martinez. The 2016 updated WHO classification of lymphoid neoplasias , 2017, Hematological oncology.
[12] B. Nathwani,et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project , 2016, Haematologica.
[13] J. Byrd,et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[14] P. Kao,et al. Update on Diagnosis and Management , 2015 .
[15] A. Lupu,et al. Indolent lymphoma: diagnosis and prognosis in medical practice. , 2013, Maedica.
[16] S. Clarke,et al. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO , 2009, BMC Cancer.